All of the Above: Diarrhea, Headache, and Skin Irritation
Based on the most recent guideline evidence, the medication in question (roflumilast cream) is associated with all of the listed adverse effects: diarrhea, headache, and skin irritation (application site pain), making option D the correct answer 1.
Evidence from High-Quality Guidelines
The 2025 American Academy of Dermatology guidelines specifically document that roflumilast cream's most common adverse events (≥1% in any arm) include:
- Headache
- Diarrhea
- Nausea
- Vomiting
- Application site pain (skin irritation) - reported in 1.5% of roflumilast-treated patients compared to 0.7% of vehicle-treated patients 1
Temporal Pattern and Severity
The gastrointestinal adverse effects (diarrhea, nausea) follow a predictable pattern 1:
- 70-80% occur within the first 2 weeks of treatment
- 75-80% are mild in severity
- 60-65% resolve within the first month
This temporal clustering is important for patient counseling and expectation management.
Supporting Evidence from Related Medications
The 2020 Joint AAD-NPF guidelines for apremilast (another PDE-4 inhibitor) corroborate this adverse effect profile, listing the identical triad of diarrhea, headache, and upper respiratory tract infections as the most common adverse effects 2. This consistency across PDE-4 inhibitors strengthens the evidence that these are class effects.
Clinical Implications
Despite these adverse effects, both guidelines emphasize that these medications are "well tolerated with limited anticipated adverse effects" 1. The key distinction is that while these side effects occur, they are:
- Generally mild in severity
- Often self-limiting
- Rarely lead to discontinuation (rates were low and similar across treatment groups)
Common Pitfall to Avoid
Do not dismiss patient reports of these symptoms as unrelated to the medication. While the adverse effects are typically mild, acknowledging them validates patient experience and improves adherence. Proper pre-treatment counseling about the expected timeline (especially for GI symptoms peaking early then resolving) can prevent premature discontinuation.